Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer

ConclusionsFrom our data we conclude that AURKA and TPX2 may act as KRAS biomarkers in PDAC that can predict a worse prognosis, and that AURKA or TPX2 targeting in PDAC cells may reduce their transformed phenotype. These results indicate that AURKA and TPX2 may serve as promising targets to be explored forKRAS-mutant PDAC therapy.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research